The PTC ST-920 acquisition has closed, giving PTC Therapeutics (NASDAQ: PTCT) control of a late-stage gene-therapy program for Fabry disease. PTC acquired the asset from Sangamo Therapeutics (NASDAQ: SGMO) after winning a competitive bankruptcy auction.
ST-920, also known as isaralgagene civaparvovec, is designed as a one-time treatment that delivers a functional gene for the enzyme deficient in Fabry disease. PTC expects to complete a rolling U.S. biologics license application for accelerated approval in the fourth quarter of 2026.
PTC ST-920 Acquisition Adds a BLA-Stage Program
PTC confirmed the closing in an official company announcement. When it first disclosed the planned purchase in August, the company said the terms included $111 million upfront and as much as $100 million in regulatory milestone payments.
The planned application is based on the Phase 1/2 STAAR study. PTC says the therapy produced durable alpha-galactosidase A activity and clinical benefits while reducing dependence on enzyme-replacement therapy, but regulators will independently assess the evidence.
ST-920 has received U.S. orphan-drug, Fast Track and regenerative-medicine advanced-therapy designations. Those designations can facilitate development and review, but they do not guarantee approval.
Regulatory Review Is the Next Major Test
Fabry disease is an inherited disorder caused by mutations in the GLA gene. The resulting enzyme deficiency can allow damaging substances to accumulate in organs, creating a need for long-term treatment.
PTC expects its existing rare-disease regulatory and commercial infrastructure to support the program. That could reduce the need to build a separate launch organization, although manufacturing consistency, safety follow-up and payer access remain central challenges for gene therapies.
An accelerated-approval pathway can allow earlier market entry based on evidence reasonably likely to predict clinical benefit. It can also require confirmatory evidence after approval, leaving development obligations in place even if the initial review is successful.
Closing removes transaction uncertainty, but the investment case now turns to completion and acceptance of the application, the FDA’s assessment and the eventual label. Any delay or request for more evidence could change the timing and economics of a potential commercial launch.
